Cepheid provides molecular diagnostic testing for various health conditions, including infectious diseases and oncology. It offers diagnostic systems and services to healthcare professionals.

Steve Young

Allen Northrup

Dennis H. Giesing

Cepheid

Advanced Bionics designs and manufactures cochlear implants and hearing technology, self-described as providing solutions for individuals with hearing loss.

Advanced Bionics

B. Braun is a medical technology company that provides a range of products and services related to healthcare.

B. Braun

Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Alice Schwartz

David Schwartz

Bio-Rad Laboratories, Inc.

Danaher Corporation

Cepheid is dedicated to improving healthcare by pioneering molecular diagnostics that combine speed, accuracy, and flexibility. The company's GeneXpert® systems and Xpert® tests automate highly complex and time-consuming manual procedures, providing A Better Way for institutions of any size to perform world-class PCR testing. Cepheid’s broad test portfolio spans respiratory infections, blood virology, women’s and sexual health, TB and emerging infectious diseases, healthcare-associated infectious diseases, oncology and human genetics. The company’s solutions deliver actionable results where they are needed most – from central laboratories and hospitals to near-patient settings. For more information, visit http://www.cepheid.com.

Cepheid is proud to be a part of Danaher. Danaher’s science and technology leadership puts Cepheid’s solutions at the forefront of the industry, so they can reach more people. Being part of Danaher means we can offer unparalleled breadth and depth of expertise and solutions to our customers.

Together with Danaher’s other businesses across Biotechnology, Diagnostics, and Life Sciences, we unlock the transformative potential of cutting-edge science and technology to improve billions of lives every day.

U.S. Department of Defense

U.S. Department of Health & Human Services

Biomedical Advanced Research and Development Authority (BARDA)

Wheatley Partners

Innogenetics

Accurate detection of GroupA Strep supports antimicrobial stewardship and may reduce the number of patients inappropriately prescribed antibiotics. #RespiratoryHealth #StrepA

Learn more: https://lnkd.in/eRXv7Qu6

Cepheid receives expanded FDA clearance with CLIA Waiver for Xpert® Xpress MVP. We are committed to providing expanded access to #WomensHealth and #SexualHealth with PCR testing at the POC. Read all about it:

https://ow.ly/RKQu50QsbNg

There are approximately 11,500 new cases of cervical cancer diagnosed in the U.S. annually.* #CervicalCancerAwareness #MolecularDiagnostics 

*https://ow.ly/u42E50Qrv0i

Learn more about our Women’s Health and other testing solutions: https://ow.ly/Uqun50Qrv0h

Today we are honored to launch a new collaboration with the Innovative Genomics Institute (IGI) to develop a gene-editing solution designed to be easily modified to address potentially hundreds of devastating illnesses.

The Danaher-IGI Beacon for CRISPR Cures will take a revolutionary approach to genomic medicine, aiming to use CRISPR-based gene editing to permanently address the genetic causes of rare diseases with a unified technological approach.

By combining the R&D and manufacturing talent, technology and expertise of several Danaher businesses with the complementary academic research strengths at the IGI, we are dedicated to delivering on the enormous therapeutic promise of CRISPR for patients. https://bit.ly/48K8YbA

Aldevron Beckman Coulter Life Sciences Cytiva Integrated DNA Technologies Leica Biosystems Leica Microsystems Jennifer Doudna Fyodor Urnov

Cepheid is committed to providing expanded access to women’s and #sexualhealth with PCR testing at the POC. We’re excited to introduce Xpert® Xpress MVP, a multiplex vaginal panel to aid in the diagnosis of Bacterial Vaginosis, Vulvovaginal Candidiasis, and Trichomoniasis for use in near-patient settings, with results in as soon as 60 min. Learn more: https://ow.ly/yjUt50QnTr7

Happy New Year. We wish you a happy, healthy, and peaceful 2024.

Hosting the Mayor of Markham, Ontario, Frank Scarpitti, at Cepheid Canada this month was a pleasure. Thank you for sharing our passion for innovation and improving patient outcomes with real-time PCR. #BestTeamWins #Cepheid #MolecularDiagnostics #MultiplexPCR #LabInACartridge

Wishing you all the joys of the season and happiness throughout the coming year. Best wishes from your friends at Cepheid.

Metric
Company Name	Cepheid	Advanced Bionics	B. Braun	Bio-Rad Laboratories, Inc.
Symbol				BIO
MSH ID	COM:CEPHEID	COM:ADVANCEDBIONICS	COM:BBRAUN	COM:BIO-RAD
Market	PRIVATE	PRIVATE	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services	Healthcare
Industry	Healthcare Technology	Medical Devices	Medical Devices	Medical - Devices
Country	US	US	DE	US
Stage
Employee Count	4.86K			8K
Website	cepheid.com	advancedbionics.com	bbraun.com	bio-rad.com
LinkedIn				bio-rad
Founders

Metric
Market Cap			8.01B
Enterprise Value
Monthly Web Traffic	95.72K	33.21K
Web Traffic Growth	0.47	-0.65
Valuation
Raised Capital	63.80M

Metric
Revenue				2.67B
Revenue (LTM)
Revenue (NTM)
Gross Profit				1.43B
EBITDA				576.20M
Operating Income				383.80M
Net Income				-637.32M
EPS				-21.82
Diluted EPS				-21.82
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin				0.54
Operating Profit Margin				0.15
EBITDA Margin				0.22
Net Profit Margin				-0.12
Return on Equity				-0.04
Return on Assets				-0.03
Return on Capital Employed				0.04

COM:CEPHEID

Cepheid

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio				-58.35
P/B Ratio				1.10
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio				3.81
EV Multiple				16.32

Metric
Days Sales Outstanding				61.37
Days Payables Outstanding				77.12
Days Inventory Outstanding				248.85
Operating Cycle				313.70
Cash Conversion Cycle				274.47
Asset Turnover				0.26

Metric
Operating Cash Flow				374.94M
Free Cash Flow				218.26M
Cash Flow to Debt				0.30
Operating Cash Flow/Sales				0.14
Free Cash Flow Yield				0.02

Metric
Cash & Equivalents				403.97M
Accounts Receivable				11.40M
Inventory				780.52M
Goodwill				413.60M
Debt to Capitalization				0.15
Debt to Assets				0.10
Current Ratio				5.64
Quick Ratio				4.89

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue				0.02
R&D to Revenue				0.09
SG&A to Revenue